Michael Babcock, MD
Cardiovascular Disease · Savannah, GANPI 1316129661
Payments from drug & device makers
Across 292 payments — averaging $52.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$9K
- Boston Scientific$1K
- Abiomed$820
- E.r. Squibb & Sons, L.L.C.$800
- Novartis$746
- Abbott$654
- plus $2K from 30 others
What the payments were for
- Consulting fees$5,16034%
- Travel & lodging$2,70118%
- Food & beverage$7,42649%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 38 | $8,582 |
| Boston Scientific | 14 | $1,332 |
| Abiomed | 11 | $820 |
| E.r. Squibb & Sons, L.L.C. | 40 | $800 |
| Novartis | 51 | $746 |
| Abbott | 35 | $654 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 27 | $400 |
| Inari Medical, Inc. | 9 | $373 |
| Medtronic(2 entities) | 6 | $237 |
| Livanova USA, Inc. | 1 | $131 |
| GE HealthCare | 1 | $119 |
| Shockwave Medical, Inc | 4 | $108 |
| Pfizer | 6 | $102 |
| Lexicon Pharmaceuticals, Inc. | 6 | $101 |
| Siemens Medical Solutions USA, Inc. | 1 | $77 |
| Philips North America LLC | 4 | $76 |
| AstraZeneca | 5 | $66 |
| Sanofi-aventis U.S. LLC | 3 | $56 |
| Amgen | 3 | $52 |
| Cvrx, Inc. | 2 | $51 |
| Johnson & Johnson | 4 | $47 |
| Stryker | 2 | $45 |
| Boehringer Ingelheim | 2 | $37 |
| Esperion Therapeutics, Inc. | 2 | $30 |
| Akcea Therapeutics, Inc. | 2 | $30 |
| Chiesi USA, Inc. | 2 | $30 |
| Bayer | 2 | $28 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| Recor Medical Inc | 1 | $22 |
| Cardiovascular Systems Inc. | 1 | $20 |
| Supernus Pharmaceuticals, Inc. | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $17 |
| Acist Medical Systems, Inc. | 1 | $16 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $15 |
| Actelion Pharmaceuticals US, Inc. | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Transcatheter Heart Valve$6,483
- GENERAL - STRUCTURAL HEART$977
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$328
- Impella$235
- FlowTriever$189
- ClotTriever$189
- ONYX FRONTIER$155
- SAPIEN 3 Ultra RESILIA$133
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$131
- CAMZYOS$122
- OPTICROSS$118
- AMPLATZER Occluders$116
- Accent Pacemaker$105
How this compares
$15,286 in reported general payments places this provider in the 80th percentile of 640 cardiovascular disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 435 | $488,922 |
| EntrestoSacubitril/Valsartan | 245 | $340,043 |
| XareltoRivaroxaban | 58 | $60,959 |
| FarxigaDapagliflozin Propanediol | 23 | $28,692 |
| JardianceEmpagliflozin | 16 | $19,961 |
| Flecainide Acetate | 205 | $8,475 |
| Metoprolol Succinate | 330 | $4,955 |
| Ranolazine ErRanolazine | 25 | $2,695 |
| Atorvastatin Calcium | 224 | $2,195 |
| Carvedilol | 236 | $2,017 |
| Furosemide | 280 | $1,617 |
| Hydrochlorothiazide | 279 | $1,561 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 61 | $1,414 |
| Metoprolol Tartrate | 208 | $1,328 |
| Losartan Potassium | 142 | $1,120 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $102 | $488,922435 claims |
| NovartisEntresto | $746 | $340,043245 claims |
| Johnson & JohnsonXarelto | $47 | $60,95958 claims |
| AstraZenecaFarxiga | $66 | $28,69223 claims |
| Boehringer IngelheimJardiance | $37 | $19,96116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 640 cardiovascular disease providers in Georgia.
Other cardiovascular disease in Savannah
- Roy FloodSavannah$120K
- Narendra SinghJohns Creek$5.4M
- Elizabeth OfiliAtlanta$4.5M
- Sanjay YadavAtlanta$3.7M
- Arshed QuyyumiAtlanta$3.4M
- Naresh ParikhNorcross$2.8M
- Nicolas ChronosEatonton$2.4M
- Bobby KhanAtlanta$1.7M
- Hunter ChampionColumbus$1.5M
- David SuhTucker$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.